CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade IDEAYA Biosciences, Inc. - IDYA CFD

43.26
1.88%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

IDEAYA Biosciences Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 42.46
Open* 42.62
1-Year Change* 209.96%
Day's Range* 42.48 - 43.4
52 wk Range 13.29-41.63
Average Volume (10 days) 1.54M
Average Volume (3 months) 21.55M
Market Cap 2.93B
P/E Ratio -100.00K
Shares Outstanding 69.01M
Revenue 23.48M
EPS -1.94
Dividend (Yield %) N/A
Beta 0.81
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 43.26 0.47 1.10% 42.79 43.46 42.29
Mar 26, 2024 42.46 0.00 0.00% 42.46 43.13 42.06
Mar 25, 2024 42.27 -0.09 -0.21% 42.36 43.56 42.15
Mar 22, 2024 42.95 -2.31 -5.10% 45.26 45.27 42.91
Mar 21, 2024 45.54 0.33 0.73% 45.21 46.10 45.18
Mar 20, 2024 44.75 1.45 3.35% 43.30 44.81 42.72
Mar 19, 2024 44.25 1.27 2.95% 42.98 45.25 42.97
Mar 18, 2024 43.40 -0.38 -0.87% 43.78 44.32 42.97
Mar 15, 2024 44.19 -0.20 -0.45% 44.39 45.15 43.73
Mar 14, 2024 44.70 -0.13 -0.29% 44.83 45.72 43.90
Mar 13, 2024 45.66 1.33 3.00% 44.33 45.69 44.33
Mar 12, 2024 44.71 1.31 3.02% 43.40 45.80 42.98
Mar 11, 2024 43.53 -1.77 -3.91% 45.30 45.50 43.36
Mar 8, 2024 45.50 -0.50 -1.09% 46.00 47.36 44.87
Mar 7, 2024 45.15 -1.30 -2.80% 46.45 46.89 45.13
Mar 6, 2024 46.25 1.43 3.19% 44.82 47.61 44.82
Mar 5, 2024 44.74 -0.67 -1.48% 45.41 46.71 44.59
Mar 4, 2024 46.72 0.55 1.19% 46.17 47.29 45.89
Mar 1, 2024 46.14 1.47 3.29% 44.67 46.86 44.62
Feb 29, 2024 44.61 0.12 0.27% 44.49 45.56 44.44

IDEAYA Biosciences, Inc. Events

Time (UTC) Country Event
Tuesday, May 7, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 IDEAYA Biosciences Inc Earnings Release
Q1 2024 IDEAYA Biosciences Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 6, 2024

Time (UTC)

19:30

Country

US

Event

IDEAYA Biosciences Inc Annual Shareholders Meeting
IDEAYA Biosciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 50.931 27.941 19.538 0 0
Total Operating Expense 113.433 78.209 54.882 44.271 36.417
Selling/General/Admin. Expenses, Total 23.897 20.051 15.184 9.952 4.668
Research & Development 89.536 58.158 39.698 34.319 31.749
Operating Income -62.502 -50.268 -35.344 -44.271 -36.417
Interest Income (Expense), Net Non-Operating 3.847 0.506 0.849 2.288 1.994
Other, Net 0.008 0.077
Net Income Before Taxes -58.655 -49.762 -34.495 -41.975 -34.346
Net Income After Taxes -58.655 -49.762 -34.495 -41.975 -34.346
Net Income Before Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Net Income -58.655 -49.762 -34.495 -41.975 -34.346
Income Available to Common Excl. Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Income Available to Common Incl. Extra. Items -58.655 -49.762 -34.495 -41.975 -34.346
Diluted Net Income -58.655 -49.762 -34.495 -41.975 -34.346
Diluted Weighted Average Shares 41.4447 35.2524 24.7218 12.497 19.4786
Diluted EPS Excluding Extraordinary Items -1.41526 -1.41159 -1.39533 -3.35882 -1.76326
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -1.41526 -1.41159 -1.39533 -3.35882 -1.76326
Revenue 50.931 27.941 19.538
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.544 7.88 4.022 29.699 5.851
Revenue 3.544 7.88 4.022 29.699 5.851
Total Operating Expense 36.253 34.159 30.465 29.039 28.35
Selling/General/Admin. Expenses, Total 7.075 6.3 5.752 6.667 5.554
Research & Development 29.178 27.859 24.713 22.372 22.796
Operating Income -32.709 -26.279 -26.443 0.66 -22.499
Interest Income (Expense), Net Non-Operating 4.783 2.639 2.242 0.955 0.443
Net Income Before Taxes -27.926 -23.64 -24.201 1.615 -22.056
Net Income After Taxes -27.926 -23.64 -24.201 1.615 -22.056
Net Income Before Extra. Items -27.926 -23.64 -24.201 1.615 -22.056
Net Income -27.926 -23.64 -24.201 1.615 -22.056
Income Available to Common Excl. Extra. Items -27.926 -23.64 -24.201 1.615 -22.056
Income Available to Common Incl. Extra. Items -27.926 -23.64 -24.201 1.615 -22.056
Diluted Net Income -27.926 -23.64 -24.201 1.615 -22.056
Diluted Weighted Average Shares 56.2511 48.3701 48.2055 41.1096 38.661
Diluted EPS Excluding Extraordinary Items -0.49645 -0.48873 -0.50204 0.03929 -0.5705
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.49645 -0.48873 -0.50204 0.03929 -0.5705
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 370.454 250.996 288.605 101.654 90.667
Cash and Short Term Investments 364.829 246.77 283.585 98.956 89.961
Cash & Equivalents 68.632 92.046 72.037 34.067 20.505
Short Term Investments 296.197 154.724 211.548 64.889 69.456
Prepaid Expenses 5.414 3.123 3.143 2.698 0.706
Total Assets 387.969 381.347 298.269 113.001 96.541
Property/Plant/Equipment, Total - Net 8.993 8.661 9.476 9.699 5.152
Property/Plant/Equipment, Total - Gross 16.546 14.258 13.37 12.215 6.435
Accumulated Depreciation, Total -7.553 -5.597 -3.894 -2.516 -1.283
Other Long Term Assets, Total 0.205 0.397 0.188 0.122 0.722
Total Current Liabilities 31.718 45.159 38.64 6.94 5.413
Accounts Payable 4.28 2.1 0.953 0.709 1.417
Accrued Expenses 18.87 14.019 10.056 6.168 3.583
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 8.568 29.04 27.631 0.063 0.413
Total Liabilities 38.514 79.833 99.995 12.601 7.098
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Other Liabilities, Total 6.796 34.674 61.355 5.661 1.685
Total Equity 349.455 301.514 198.274 100.4 89.443
Redeemable Preferred Stock 0 97.656
Preferred Stock - Non Redeemable, Net 0 40.735
Common Stock 0.005 0.004 0.003 0.002 0
Additional Paid-In Capital 587.724 478.97 325.25 192.824 1.599
Retained Earnings (Accumulated Deficit) -235.403 -176.748 -126.986 -92.491 -50.516
Other Equity, Total -2.871 -0.712 0.007 0.065 -0.031
Total Liabilities & Shareholders’ Equity 387.969 381.347 298.269 113.001 96.541
Total Common Shares Outstanding 48.1932 38.5331 29.5372 20.3395 19.4786
Long Term Investments 8.317 121.293 1.526
Total Receivables, Net 0.211 1.103 1.877
Accounts Receivable - Trade, Net 0.211 1.103 1.877
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 482.182 501.788 343.958 370.454 393.437
Cash and Short Term Investments 468.751 493.716 339.47 364.829 386.244
Cash & Equivalents 151.85 102.843 67.237 68.632 101.954
Short Term Investments 316.901 390.873 272.233 296.197 284.29
Total Receivables, Net 6.703 0.16 0.468 0.211 3.449
Accounts Receivable - Trade, Net 6.703 0.16 0.468 0.211 3.449
Prepaid Expenses 6.728 7.912 4.02 5.414 3.744
Total Assets 532.942 527.557 364.746 387.969 410.907
Property/Plant/Equipment, Total - Net 7.539 8.562 8.828 8.993 9.527
Property/Plant/Equipment, Total - Gross 16.523 16.911 16.915 16.546 16.527
Accumulated Depreciation, Total -8.984 -8.349 -8.087 -7.553 -7
Long Term Investments 42.394 16.377 11.74 8.317 7.691
Other Long Term Assets, Total 0.827 0.83 0.22 0.205 0.252
Total Current Liabilities 24.893 25.337 29.82 31.718 32.727
Accounts Payable 5.169 5.868 4.376 4.28 3.645
Accrued Expenses 18.285 16.651 19.189 18.87 18.815
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.439 2.818 6.255 8.568 10.267
Total Liabilities 24.893 25.948 30.936 38.514 42.138
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0.611 1.116 6.796 9.411
Total Equity 508.049 501.609 333.81 349.455 368.769
Common Stock 0.006 0.006 0.005 0.005 0.005
Additional Paid-In Capital 823.202 789.751 594.253 587.724 583.968
Retained Earnings (Accumulated Deficit) -314.409 -286.969 -259.043 -235.403 -211.202
Other Equity, Total -0.75 -1.179 -1.405 -2.871 -4.002
Total Liabilities & Shareholders’ Equity 532.942 527.557 364.746 387.969 410.907
Total Common Shares Outstanding 58.6264 57.4403 48.3904 48.1932 48.0904
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -58.655 -49.762 -34.495 -41.975 -34.346
Cash From Operating Activities -87.175 -55.779 55.463 -39.313 -27.62
Cash From Operating Activities 2.101 1.725 1.381 1.245 0.886
Non-Cash Items 10.934 10.071 4.171 1.701 4.186
Cash Taxes Paid 0 0.004 0.001 0.001 0.001
Cash Interest Paid 0.06 0.071 0.082 0.091 0.099
Changes in Working Capital -41.555 -17.813 84.406 -0.284 1.654
Cash From Investing Activities -33.404 -69.666 -146.243 2.265 -63.179
Capital Expenditures -3.443 -2.644 -0.493 -1.353 -1.708
Other Investing Cash Flow Items, Total -29.961 -67.022 -145.75 3.618 -61.471
Cash From Financing Activities 97.165 145.454 128.75 50.61 105.378
Financing Cash Flow Items 0 0 19.988 0 -0.071
Issuance (Retirement) of Stock, Net 97.165 145.454 108.762 50.61 105.449
Net Change in Cash -23.414 20.009 37.97 13.562 14.579
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -23.64 -58.655 -34.454 -36.069 -14.013
Cash From Operating Activities -27.842 -87.175 -63.805 -39.639 -19.647
Cash From Operating Activities 0.588 2.101 1.543 0.974 0.464
Non-Cash Items 2.102 10.934 9.086 6.167 2.954
Cash Taxes Paid 0 0 0
Cash Interest Paid 0.013 0.06 0.046 0.032 0.016
Changes in Working Capital -6.892 -41.555 -39.98 -10.711 -9.052
Cash From Investing Activities 23.521 -33.404 -23.128 -4.445 -17.761
Capital Expenditures -0.043 -3.443 -3.443 -2.342 -0.401
Other Investing Cash Flow Items, Total 23.564 -29.961 -19.685 -2.103 -17.36
Cash From Financing Activities 2.926 97.165 96.841 1.144 0.653
Issuance (Retirement) of Stock, Net 2.926 97.165 96.841 1.144 0.653
Net Change in Cash -1.395 -23.414 9.908 -42.94 -36.755
Financing Cash Flow Items 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

IDEAYA Biosciences, Inc. Company profile

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and Werner Helicase, in high microsatellite instability tumors (MSI) tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Ideaya Biosciences Inc revenues increased 43% to $27.9M. Net loss increased 44% to $49.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balanci increase of 42% to $54.7M (expense), Stock-based Compensation in SGA increase from $1.2M to $4.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

7000 Shoreline Ct Ste 350
SOUTH SAN FRANCISCO
CALIFORNIA 94080-7604
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,587.80 Price
+2.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.63 Price
+1.470% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,211.23 Price
+0.820% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

18,278.60 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading